

## **XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology**

March 4, 2015 9:40 AM ET

Mar 4, 2015

AUSTIN, Texas, March 4, 2015 /PRNewswire/ -- XBiotech announced today that results from its Phase II pilot study in patients with moderate to severe plaque psoriasis have been published in JAMA Dermatology. The open-label Phase II trial evaluated the potential benefit of MABp1, the Company's True Human™ monoclonal antibody that targets interleukin-1 alpha (IL-1a). IL-1a is a pro-inflammatory cytokine present in keratinocytes and inflammatory cells present in skin lesions. The Company claims that blockade of IL-1a can be a safe and effective treatment for many dermatologic conditions, including psoriasis. This study also demonstrates use of XBiotech's True Human™ technology, which utilizes antibodies that naturally occur in human beings (as opposed to being engineered in vitro), which reportedly have the potential to be safer and more effective than other non-naturally occurring antibodies.

The article outlines the outcome of eight patients enrolled in the study, all of which had moderate to severe plaque psoriasis with a minimum Psoriasis Area and Severity index (PASI) score of 12. All patients received a 200 mg dose of MABp1 as a monotherapy. The dose was administered subcutaneously every three weeks with follow-ups at day 56 and 70 to assess efficacy and pharmacokinetics, respectively.

The manuscript notes exceptional safety and tolerability and reveals that by day 56, 63% of patients had an improved PASI score of 25, 38% had a PASI score of 50 and 13% had a score of 75. It was reported that although the trial was relatively small in size, the tolerability and clinical responses observed were very encouraging.

Michael Stecher, the Company's Medical Director added, "The results highlighted in this publication I believe strongly demonstrate the potential of targeting IL-1a for the treatment of psoriasis and we very much hope to provide a safe and effective treatment for this prevalent and devastating disease in the future."

### **ABOUT XBIOTECH**

XBiotech is a leading developer of next generation therapeutic antibodies. The Company is also innovating with manufacturing technology and clinical strategies to lessen capital requirements and reduce lead times for drug development.

#### **Contact:**

Ashley Otero

XBiotech

[aotero@xbiotech.com](mailto:aotero@xbiotech.com)

512.386.2930

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/xbiotech-announces-phase-ii-psoriasis-study-results-in-jama-dermatology-300045523.html>

SOURCE XBiotech